Advertisement
Advertisement
RLAY
Relay Therapeutics, Inc. Common Stock
19.44
USDSponsored
-0.26
-1.32%
Aug 21, 15:59 UTC -4
Closed
After-Market
19.75
+0.31
+1.59%
RLAY Earnings Reports
Positive Surprise Ratio
RLAY beat 14 of 25 last estimates.
56%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.00M
/-$0.40
Implied change from Q2 26 (Revenue/ EPS)
+470.71%
/-2.44%
Implied change from Q3 25 (Revenue/ EPS)
--
/-6.98%
Relay Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, RLAY reported earnings of -0.41 USD per share (EPS) for Q2 26, missing the estimate of -0.39 USD, resulting in a -2.78% surprise. Revenue reached 350.00 thousand, compared to an expected 890.18 thousand, with a -60.68% difference. The market reacted with a +0.10% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 2.00 million USD, implying an decrease of -2.44% EPS, and increase of 470.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Relay Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Relay Therapeutics, Inc. Common Stock reported EPS of -$0.41, missing estimates by -2.78%, and revenue of $350.00K, -60.68% below expectations.
How did the market react to Relay Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.1%, changed from $19.75 before the earnings release to $19.77 the day after.
When is Relay Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Relay Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Relay Therapeutics, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $2.00M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement